CEBPA and neoplasm: During the prognosis study, AML patients with CEPBA mutations showed selective upregulation of some miRNAs, including several members in the miR‐181 family, compared to patients without mutation.[[qv: 7d]] In our previous work, we had found target sequences of C/EBPα‐p30 in the promoter upstream of the miR‐181a‐1 gene, and subsequently confirmed its transactivity by C/EBPα‐p30 via luciferase array.[[qv: 7c]] Since miR‐181a is known to be tumor suppressive, such a discovery provided possible explanation of the clinical observations.